10-Q: Allogene Therapeutics Reports Q3 2024 Results, Prioritizes Core Programs

Allogene Therapeutics reports a net loss of $66.3 million for Q3 2024, focusing on core programs and advancing clinical trials.

Summary

• Allogene Therapeutics reported a net loss of $66.3 million for the third quarter of 2024, and a net loss of $197.7 million for the nine months ended September 30, 2024.
• The company's cash and cash equivalents and investments totaled $403.4 million as of September 30, 2024, which is expected to fund operations into 2026.
• Research and development expenses were $44.7 million for the quarter and $147.3 million for the nine months ended September 30, 2024.
• The company is prioritizing four core programs, including cema-cel in large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL), ALLO-316 in renal cell carcinoma (RCC), and ALLO-329 for autoimmune diseases (AID).
• A pivotal Phase 2 clinical trial (ALPHA3) for cema-cel as a first-line treatment for LBCL was initiated in June 2024, with enrollment expected to complete in the first half of 2026.
• The company is enrolling a Phase 1 clinical trial (TRAVERSE) of ALLO-316 in adult patients with advanced or metastatic clear cell RCC, with additional data expected in mid-2025.
• An investigational new drug (IND) application for ALLO-329 is planned for the first quarter of 2025, with a Phase 1 trial expected to begin in mid-2025.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While there are positive developments in clinical trials and strategic partnerships, the significant net losses, reliance on third parties, and identified material weakness in internal controls temper the overall sentiment. The company is making progress but faces significant challenges.

Positives

• The company has a strong cash position of $403.4 million, providing a runway into 2026.
• The initiation of the pivotal Phase 2 ALPHA3 trial for cema-cel is a significant milestone.
• The Phase 1 trial of ALLO-316 showed promising response rates in RCC patients with a CD70 TPS of 50%.
• The RMAT designation for ALLO-316 could expedite its development and regulatory review.
• The expansion of the CD19 license territory significantly increases the market opportunity for cema-cel.
• The company is advancing a pipeline of allogeneic CAR T cell product candidates targeting multiple antigens.

Negatives

• The company reported a net loss of $66.3 million for Q3 2024 and $197.7 million for the nine months ended September 30, 2024.
• The company has incurred significant operating losses since inception, with an accumulated deficit of $1.8 billion.
• The company has identified a material weakness in its internal control over financial reporting.
• The company is reliant on third parties for manufacturing and clinical trials, which could lead to delays or failures.
• The company faces significant competition from other biotechnology and pharmaceutical companies.
• The company's product candidates are based on novel technologies, which makes it difficult to predict the time and cost of development and the likelihood of regulatory approval.

Risks

• The company's product candidates may cause undesirable side effects or have other properties that could halt clinical development or prevent regulatory approval.
• Clinical trials may fail to demonstrate the safety and efficacy of product candidates, preventing or delaying regulatory approval and commercialization.
• The company may encounter substantial delays in clinical trials or may not be able to conduct trials on expected timelines.
• The company may fail to successfully manufacture product candidates or obtain regulatory approval to utilize or commercialize from its manufacturing facility or at a CDMO.
• The company is heavily reliant on partners, Cellectis and Servier, for access to TALEN gene editing technology.
• Servier's discontinuation of involvement in the development of CD19 products and disputes with Cellectis may have adverse consequences.
• The company relies on third parties to conduct clinical trials, and if these third parties do not successfully carry out their duties, the company may not be able to obtain regulatory approval or commercialize product candidates.
• The company relies on T cells from healthy donors, and if an adequate supply is not obtained, development and commercialization may be adversely impacted.
• The company depends on intellectual property licensed from third parties, and termination of these licenses could result in the loss of significant rights.
• The company has identified a material weakness in its internal control over financial reporting, which could affect its ability to report results accurately and in a timely manner.

Future Outlook

The company expects its cash and cash equivalents and investments will be sufficient to fund its operations for at least the next 12 months from the date the unaudited condensed consolidated financial statements are filed with the SEC. The company expects to continue to incur net losses for the foreseeable future and expects research and development and general and administrative expenses to increase. The company intends to raise additional capital through the issuance of equity securities, debt financings or other sources in order to further implement its business plan.

Management Comments

• Management expects to incur additional losses in the future to fund its operations and conduct product research and development and recognizes the need to raise additional capital to fully implement its business plan.
• Management expects that its cash and cash equivalents and investments will be sufficient to fund its operations for at least the next 12 months from the date the accompanying unaudited condensed consolidated financial statements are filed with the Securities and Exchange Commission (SEC).

Industry Context

The announcement reflects the ongoing challenges and opportunities in the immuno-oncology and cell therapy space, where companies are balancing the need for innovation with the high costs and risks associated with clinical development. The focus on core programs and strategic partnerships is a common approach in this competitive landscape.

Comparison to Industry Standards

• Allogene's cash runway into 2026 is relatively strong compared to many other clinical-stage biotech companies, providing a longer period to achieve key milestones.
• The reported net losses are typical for a company at this stage of development, where significant investments are being made in research and clinical trials.
• The clinical trial results for ALLO-316, with a 50% best overall response rate in a subset of patients, are promising compared to some other early-stage trials in solid tumors, but further data is needed to confirm these results.
• The expansion of the CD19 license territory is a strategic move to increase market potential, similar to other companies seeking to maximize the value of their assets.
• The company's focus on allogeneic CAR T cell therapy is in line with the industry trend towards off-the-shelf therapies, which offer advantages over autologous therapies in terms of scalability and accessibility.
• The company's reliance on third-party manufacturers and CROs is a common practice in the biotech industry, but it also introduces risks that need to be carefully managed.

Related Party Transactions

• The company recognized collaboration revenue from Allogene Overland PRC.
• The company recorded rent expense related to a sublease agreement with Bellco Capital LLC.
• The company incurred costs for services provided under a consulting agreement with Bellco Capital LLC.

Stakeholder Impact

• Shareholders may be concerned about the company's ongoing losses and the need for additional capital.
• Employees may be affected by the company's reduction in force and the uncertainty surrounding future growth.
• Patients may benefit from the development of new therapies, but they also face risks associated with clinical trials.
• Suppliers and partners may be affected by the company's financial performance and strategic decisions.
• Creditors may be concerned about the company's ability to repay its debts.

Next Steps

• Complete enrollment in the ALPHA3 trial in the first half of 2026.
• Announce additional data from the Phase 1b expansion cohort of the TRAVERSE trial in mid-2025.
• File an IND application for ALLO-329 in the first quarter of 2025.
• Initiate the Phase 1 trial with ALLO-329 in mid-2025.
• Continue to evaluate clinical development and commercial opportunities for cema-cel in CLL/SLL and provide an update in early 2025.

Key Dates

Keywords

Allogene Therapeutics, CAR T cell therapy, allogeneic, immuno-oncology, clinical trials, cemacabtagene ansegedleucel, ALLO-316, ALLO-329, lymphoma, leukemia, renal cell carcinoma, autoimmune disease, RMAT designation, FDA, regulatory approval, biotechnology, gene editing, TALEN, CD19, CD70, BCMA